Plasma and plasma components in the management of disseminated intravascular coagulation Marcel Levi* Academic Medical Center, University of Amsterdam,

Slides:



Advertisements
Similar presentations
Coagulopathy and blood component transfusion in trauma
Advertisements

Disseminated Intravascular Coagulation Robert R. Zaid D.O. Genesys Regional Medical Center PGY-I.
Brad Beckham T4. Definitions  Major blood loss Hemoglobin concentration below 6-10 g/dl  Massive transfusion in adults >9 erythrocyte units within 24h.
Coagulation-Anticoagulation Balance and Imbalance of Haemostatic System.
Haematology. Help I need blood! Both O negative and group specific are unsuitable for patients with antibodies…
Disseminated Intravascular Coagulation
 An acquired syndrome characterized by systemic intravascular coagulation  Coagulation is always the initial event.  Most morbidity and mortality depends.
Initiation substances activate s by proteolysis a cascade of circulating precursor proteins which leads to the generation of thrombin which in turn converts.
BLOOD BANKING 1- BLOOD PRODUCTS 2- AUTOLOGOUS TRANSFUSION M. H. Shaheen Maadi Armed Forces Hospital.
ANAESTHESIA AND ANTICOAGULANTS
ACQUIRED COAGULATION ABNORMALITIES
Haemostasis Tiffany Shaw MBChB II Haemostasis Pathway Injury Collagen exposure Tissue Factor Platelet adhesion Coagulation Cascade Release reaction.
Cristy M. Thomas FNP-BC University of Nevada School of Medicine University Medical Center, Las Vegas NV Nevada’s Only Level 1 Adult Trauma, Level 2 Pediatric.
Vascular Pharmacology
Pathology of Coagulation I- Deficiency of Coagulation Factors II- II- HYPERCOAGULABLE STATES.
D - DEATH I - IS C - COMING DIC is an important contributor to maternal mortality and morbidity.
Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia – A review Crit Care Med 2006 March Vol.34 p Ri.
Disseminated intravascular coagulation (DIC)
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
4th year medical students Blood Component Therapy Salwa I Hindawi MSc FRCPath CTM Director of Blood Transfusion Services KAUH. Jeddah.
BLEEDING DISORDERS.
DIC Disseminated intravascular coagulation
Hemostasis and Blood Coagulation
Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.
HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Intravascular Coagulation.
Approach to Bleeding Disorders
Scheme of Coagulation F XIIF XIIa F XIF XIa F IX F X F IXa F VIIaF VII Extrinsic System Tissue damage Release of tissue thromboplastine (F III) Intrinsic.
DIC Dr MB Dhlamini Department of Molecular Medicine and Haematology WITS University.
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
Disseminated intravascular coagulation
MLAB 1227: Coagulation Keri Brophy-Martinez Coagulation Disorders: Secondary Hemostasis Part Two.
Disseminated intravascular coagulation Dr. S. Parthasarathy MD., DA., DNB, MD (Acu), Dip. Diab. DCA, Dip. Software statistics, PhD(physiology) Mahatma.
DIC disseminated intravascular coagulation DIC is characterized by widespread coagulation and bleeding in the vascular compartment. DIC begins with massive.
Disseminated Intravascular Coagulation (DIC) 【 Change of basic pathology 】 【 Change of basic pathology 】 Key change Key change This fine homeostatic.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Emergency Nursing CHAPTER 33 PART 2. 2 Clinical Signs of Pain  Vocalization  Depression  Anorexia  Tachypnea  Tachycardia  Abnormal blood pressure.
Disseminated Intravascular Coagulation. XIIa Coagulation cascade IIa Intrinsic system (surface contact ) XII XI XIa Tissue factor IX IXa VIIa VII VIIIVIIIa.
Preoperative Methylprednisolone Administration Maintains Coagulation Homeostasis in Patients Undergoing Liver Resection: Importance of Inflammatory Cytokine.
Basic Clinician Training Module 6
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
Investigation of Haemostasis MS. c. program Lab-9.
Fibrinolysis and Hyperfibrinolysis TEG Analysis
Hematology Blueprint PANCE Blueprint. Coagulation Disorders.
DIC. acute, subacute or chronic widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes the natural.
Coagulation Disorders and Disseminated Intravascular Coagulation (DIC)
Haemostasis. Indications for hemostasis test – Identify patients presenting with bleeding that have a correctable bleeding tendency – Identify patients.
Chapter 38 Hematologic Disorders and Oncologic Emergencies Unit 8 Multisystem Alterations Seventh Edition Linda D. Urden Kathleen M. Stacy Mary E. Lough.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Systemic anticoagulation during ECMO is intended to control thrombin generation and limit the risk for thrombotic and hemorrhagic complications.
Bleeding Tendency Dr. Mervat Khorshied Ass. Prof. of Clinical and Chemical Pathology.
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
Obada Al-Eisa Saud Bashtawy Emad Mansour.  It is an acquired condition characterized by massive activation of the coagulation system.  It is always.
IN THE NAME OF GOD Disseminated Intravascular Coagulation Dr.h-kayalhaAnesthesiologist.
Coagulation ICU – RLH Mike Cunningham 11 th December 2008.
DIC Disseminated intravascular coagulation (DIC) is a
Immune thrombocytopenia purpura(ITP)
Prothrombin complex concentrate
Recent advances- Novoseven
Activation of the Hemostatic System During Cardiopulmonary Bypass
Constituents of the blood: Platelets and plasma
Disseminated intravascular coagulation (DIC)
Disseminated Intravascular Coagulation
The Hematologic System as a Marker of Organ Dysfunction in Sepsis
Intra vascular anti-coagulants
Disseminated intravascular coagulation (DIC) + Thrombotic microangiopathies (TTP+HUS) Ali Al Khader, M.D. Faculty of Medicine Al-Balqa’ Applied University.
Disseminated intravascular coagulation (DIC)
 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.
Drugs Affecting Blood.
Presentation transcript:

Plasma and plasma components in the management of disseminated intravascular coagulation Marcel Levi* Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands Best Practice & Research Clinical Haematology Vol. 19, No. 1, pp. 127–142, 2006

Disseminated intravascular coagulation (DIC) Not a disease entity on itself but is always associated to an underlying disease Syndrome characterized by systemic intravascular activation of coagulation leading to widespread deposition of fibrin in the circulation Microvascular dysfunction and contributes to organ failure Bleeding from various sites

Clinical conditions associated with DIC Sepsis/severe infection (any microorganism). Trauma (e.g. polytrauma, neurotrauma, fat embolism). Organ destruction (e.g. severe pancreatitis). Malignancy: solid tumours myeloproliferative/lymphoproliferative malignancies. Obstetrical calamities: amniotic fluid embolism, abruptio placentae. Vascular abnormalities: Kasabach–Merrit syndrome, large vascular aneurysms Severe hepatic failure. Severe toxic or immunological reactions: snake bites, recreational drugs transfusion reactions transplant rejection.

Pathogenesis of DIC Anti-thrombin Protein C system TF pathway inhibitor

Diagnosis of DIC

Management of DIC Cornerstone treatment : treatment of the underlying disorder Supportive treatment directed towards the coagulation system may be essential in restoring microvascular failure and reducing organ dysfunction

Plasma and platelet substitution therapy Anticoagulants Restoration of anticoagulant pathways Therapeutic consequences

Plasma and platelet substitution therapy Patients with active bleeding Those requiring an invasive procedure or otherwise at risk for bleeding complications Fresh frozen plasma & platelets vs whole blood exchange  no specific motality change Large volumes of plasma : correct coagulation defect : Factor V defect by prothrombin complex concentrate : Fibrinogen by purified coagulation factor concentrates or cryoprecipitate

Vitamin K: repeated monitoring PT, aPTT Platelet transfusion: DIC and severe thrombocytopenia (particular bleeding sign) Bleeding & platelet count <5 만 Non-bleeding patients : a much lower threshold (usually <1-2 만 )

Anticoagulants Heparin treatment :can at least partly inhibit the activation of coagulation in sepsis and other causes of DIC : debatable in DIC patients who are prone to bleeding : overt thromboembolism or extensive fibrin deposition (ex) purpura fulminans or acral ischaemia

TFPI (tissue factor pathway inhibitor) treatment : directed against TF activity  theoretically, the most logical anticoagulant agent to use in DIC : recombinant TFPI, inactivated factor VIIa, a potent and specific inhibitor of the ternary complex between TF-factor VIIa and factor Xa etc. : more favorable outcome.

Restoration of anticoagulant pathways Antithrombin III (AT III) : one of the most important physiological coagulation inhibitors : benefect in improvement of laboratory parameters, shortening of the duration of DIC, improvement organ function : being used very high doses of AT concentrate (to supraphysiological plasma levels)

Antithrombin III (AT III) : modest reduction in mortality in AT-treated patients. (not reach statistical significance in any of the trials) : A large-scale, multicentre, randomized controlled trial to address this issue directly showed no significant reduction in mortality of septic patients

Activated protein C (recombinant human activated protein C) : depression of the protein C system in DIC : lowering duration of mechanical ventilation, shock and length of stay in ICU, days free of systemic inflammatory response. : reduction in D-dimer, Median IL-6  the potential anti-inflammatory effect in patients with sepsis.

Activated protein C : shown the highest benefit of activated protein C treatment : effective in patients with normal protein C  administering activated protein C rather the zymogen protein C in septic patients : decreased mortality, coagulation and inflammation, organ function scores